MS-553 is under clinical development by MingSight Pharmaceuticals and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MS-553’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MS-553 overview

MS-553 is under development for the treatment of diabetic retinopathy with macular edema, relapsed or refractory chronic lymphocytic lymphoma (CLL) or small lymphocytic lymphoma (SLL), b-cell non-Hodgkin lymphoma, mantle cell lymphoma. It is administered orally. MS-553 crosses the blood-retina barrier to achieve high concentrations in the retina. It is a new chemical entity.

MingSight Pharmaceuticals overview

MingSight Pharmaceuticals is a pharmaceutical company that specializes in developing selective inhibitor of protein kinase C beta, MS-553 in patients with diabetic macular edema and chronic lymphocytic leukemia. The company is headquartered in San Diego, California, the US.

For a complete picture of MS-553’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.